Skip to main content

Table 2 Tumor characteristics at the time of surgery for the modified intention to treat population

From: FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

Characteristic

LET (n = 66) mean ± SD or n and %

LET + ZOL (n = 65) mean ± SD or n and %

Total (n = 131) mean ± SD or n and %

Surgery performed

   

  No

7 (10.6)

3 (4.6)

10 (7.6)

  Yes

59 (89.4)

62 (95.4)

121 (92.4)

  unknown

0

0

0

pCR

   

  No

59 (100)

62 (100)

121 (100)

  Yes

0 (0.0)

0 (0.0)

0 (0.0)

  Unknown

7

3

10

ypT

   

  0

0 (0)

0 (0)

0 (0)

  is

0 (0)

1 (1.6)

1 (0.8)

  1

23 (39.0)

23 (37.1)

46 (38.0)

  2

29 (49.2)

28 (45.2)

57 (47.1)

  3

6 (10.2)

5 (8.1)

11 (9.1)

  4

1 (1.7)

5 (8.1)

6 (5.0)

  Unknown

7

3

10

Mean patholocigal tumor size in cm

2.9 (±2.0)

2.7 (±1.7)

2.8 (±1.8)